MGP
OTLK icon

Metis Global Partners’s Outlook Therapeutics OTLK Stock Holding History

Metis Global Partners’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,414
Closed -$52.2K – 683
2022
Q4 		$52.2K Buy
2,414
+1,534
+174% +$33.4K ﹤0.01% 628
2022
Q3 		$21K Hold
880
– – ﹤0.01% 519
2022
Q2 		$18K Buy
+880
New +$25.3K ﹤0.01% 533

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Metis Global Partners's OTLK Position: Q1 2023 in Review

Metis Global Partners sold out of Outlook Therapeutics (OTLK) in Q1 2023, closing a stake of 2,414 shares — an estimated $52.2K sold.

Metis Global Partners first reported a position in OTLK in Q2 2022 and held it in 3 quarters. The position peaked at $52.2K in Q4 2022. 82 funds tracked by Wall St. Rank hold OTLK as of Q1 2023.

  • Metis Global Partners reported no remaining Outlook Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Metis Global Partners sold 2,414 Outlook Therapeutics shares in Q1 2023, an estimated $52.2K.
  • Metis Global Partners first reported a position in Outlook Therapeutics in Q2 2022 and held it in 3 quarters.
  • Metis Global Partners's Outlook Therapeutics position peaked at $52.2K in Q4 2022.
  • 82 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2023.

Based on Metis Global Partners's 13F filing for Q1 2023, filed 8 May 2023.